Finance

Lists
Why is QGEN up 2,34%?
Dive Deeper
QGEN:NYSE
Qiagen NV
USD 45,79
+2,34%
(+1,05) 1D
USD 46,01
+0,48% (+0,22)
After hours
Closed: 5 Okt., 16:00:06 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for QGEN...
Open
USD 44,78
High
USD 46,00
Low
USD 44,46
Mkt. cap
9,46 mjd
Avg. vol.
2,33 m
Volume
3,05 m
Dividend
0,76%
Quarterly dividend
USD 0,09
Ex-dividend date
07 Jul. 2026
P/E ratio
23,56
52-wk high
USD 57,82
52-wk low
USD 32,53
EPS
USD 1,94
Beta
0,61
Shares outstanding
206,08 m
No. of employees
6 k
Open
USD 44,78
High
USD 46,00
Low
USD 44,46
Mkt. cap
9,46 mjd
Avg. vol.
2,33 m
Volume
3,05 m
Dividend
0,76%
Quarterly dividend
USD 0,09
Ex-dividend date
07 Jul. 2026
P/E ratio
23,56
52-wk high
USD 57,82
52-wk low
USD 32,53
EPS
USD 1,94
Beta
0,61
Shares outstanding
206,08 m
No. of employees
6 k
News stories
From web sources and news partners
Profile
QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. European, American, Chinese, and Asian-Pacific regional headquarters are located respectively in Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore. QIAGEN's shares are listed at the NYSE and at the Frankfurt Stock Exchange in the Prime Standard. Thierry Bernard is the company's Chief Executive Officer. Wikipedia
About Qiagen NV
CEOThierry Bernard
Employees5,5 k
Founded29 Nov. 1984
HeadquartersVenlo, Limburg, Nederland
SectorHealth care
Websiteqiagen.com
Analyst
Recommendation
Action
Price target
Projected
Date
No analyst ratings found.
Last report
06 Aug. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
USD 0,62 / USD 0,60
+3,45%beat
Revenue / Est. (USD)
535,04 m / 527,46 m
+1,44%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
532,58 m
540,42 m
492,32 m
535,04 m
Cost of goods sold
187,78 m
173,92 m
168,83 m
181,97 m
Cost of revenue
187,78 m
173,92 m
168,83 m
181,97 m
Research and development expenses
48,75 m
47,24 m
48,26 m
50,43 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
143,11 m
153,88 m
142,39 m
146,77 m
Operating expense
207,51 m
218,30 m
206,24 m
212,22 m
Total operating expenses
395,29 m
392,22 m
375,06 m
394,19 m
Operating income
137,29 m
148,20 m
117,26 m
140,85 m
Other non operating income
-89,00 k
-133,00 k
193,00 k
-35,00 k
EBT including unusual items
134,73 m
109,17 m
85,83 m
132,10 m
EBT excluding unusual items
142,86 m
157,94 m
118,66 m
140,05 m
Income tax expense
4,68 m
1,34 m
17,79 m
28,70 m
Effective tax rate
3,48%
1,23%
20,72%
21,73%
Other operating expenses
-
-
-
-
Net income
130,04 m
107,83 m
68,04 m
103,40 m
Net profit margin
24,42%
19,95%
13,82%
19,33%
Earnings per share
-
0,62
0,54
0,62
Interest and investment income
15,07 m
20,00 m
10,56 m
9,36 m
Interest expense
-8,22 m
-10,14 m
-11,05 m
-10,02 m
Net interest expenses
6,85 m
9,86 m
-489,00 k
-661,00 k
Depreciation and amortization charges
-
-
-
-
EBITDA
188,26 m
179,60 m
168,47 m
191,40 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google-programme